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As physical permeation enhancers, microneedles (MNs) can modificate stratum corneum by 
creating microchannels, that are large enough to enable drugs, including macromolecules, to 
enter the skin while being small enough to avoid pain, irritation, and needle phobia [1,2]. 
Great emphasis is placed on the production process of microneedles itself, the selection of 
the most suitable materials as well as their shape, density, and size. This work aimed to 
fabricate biodegradable PLA MNs using additive manufacturing, more precisely fused 
deposition modeling (FDM) technology, and investigate the effect of varying geometry and 
print settings on the printed MNs in order to develop microneedles of optimal shape, density, 
and height. 
Ultimaker 5S 3D printer (Ultimaker, Netherlands) was used to print triangular and cylindrical 
MNs with different heights (0,6 mm, 1,2 mm, and 1,8 mm) and different number and 
orientation of single arrays on the base (5x5, 3x3, 1x5) using 2.85 mm PLA filament (3D 
Republika, Serbia). The results showed the ability of Ultimaker 5S to successfully print MNs 
with different shapes, where the triangular shape was chosen to be more acceptable for 
transdermal delivery. 1.8 mm height was chosen as the optimal height for the MNs, while the 
5 x 5 orientation of single arrays on the base resulted in more accurately printed MNs without 
a lot of waste material between the needles. Based on the results obtained, it can be 
concluded that FDM printing parameters can easily be adjusted to develop MNs of optimal 
shape, density, and height for transdermal drug delivery.  
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